Benzinga | Feb 26, 2021 07:33AM EST

Mizuho Downgrades Sage Therapeutics to Neutral, Announces $81 Price Target

Mizuho analyst Vamil Divan downgrades Sage Therapeutics (NASDAQ:SAGE) from Buy to Neutral and announces $81 price target.